CoviVac vaccination induces production of neutralizing antibodies against Delta and Omicron variants of SARS-CoV-2

Liubov Kozlovskaya; Ilya Gordeychuk; Anastasia Piniaeva; Anastasia Kovpak; Anna Shishova; Aleksandr Lunin; Elena Shustova; Vasiliy Apolokhov; Ksenia Fominykh; Yuri Ivin; Alla Kondrashova; Viktor Volok; Irina Tcelykh; Aleksandra Siniugina; Aydar Ishmukhametov

doi:10.1101/2022.02.10.22270781

Abstract

Vaccines are proven to be an effective tool in prophylaxis of severe COVID-19, but emerging mutated SARS-CoV-2 variants constantly challenge vaccines’ protectivity. We have evaluated the ability of the sera from individuals vaccinated with two variants of inactivated vaccine CoviVac and COVID-19 convalescents (May-December 2020) to neutralize SARS-CoV-2 variants Delta and Omicron. Four groups of serum samples (CoviVac vaccinees; COVID-19 convalescents; mice immunized with CoviVac preparations based on prototype B.1.1 strain and Delta variant) were evaluated in virus neutralization test against SARS-CoV-2 heterologous B.1.1 virus, Delta and Omicron variants. CoviVac preparations based on B.1.1 and Delta induced neutralizing antibodies against SARS-CoV-2 B.1.1 and two variants of concern. We observed a decrease in neutralization capacity in the sera from CoviVac (based on B.1.1 strain) vaccinees: 57.1% samples had detectable neutralizing antibodies against Delta and 61.9% against Omicron variants. Sera samples of all (100%) mice immunized with a candidate vaccine based on the SARS-CoV-2 Delta variant strain had neutralizing antibodies against all tested strains.

Competing Interest Statement

All authors are employees of the Chumakov FSC R&D IBP RAS (Institute of poliomyelitis) the developer and producer of the inactivated vaccine against coronavirus infection CoviVac. The fact did not influence the collection, analyses, or interpretation of data.

Funding Statement

This research was funded by Ministry of Science and Higher Education of the Russian Federation, АААА-А20-120081790043-5 and at the Chu-makov FSC R&D IBP RAS own expense.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants provided written informed consent before inclusion in the Clinical trials study, which cover the use of the serum samples for vaccine immunogenicity testing: 1) Ethics Committee of Kirov State Medical University of the Ministry of Health of Russia [No. 13/2020 from September 28, 2020]; 2) Ethics Committee of Healthcare Unit No. 163 of FMBA of Russia, [No.1 from October 11, 2020]; 3) Ethics Committee of Eco-Safety Scientific Research Center [No. 157 from October 1, 2020]

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes